Sudarshan Pharma Industries Q1 FY27: Revenue ₹174.41 Cr, PAT ₹5.61 Cr
Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹174Cr
- +20.1% YoY
- −21% QoQ
- Net profit
- ₹6Cr
- +41.7% YoY
- −50.8% QoQ
- Margin
- 9.12%
- +1.5 pp YoY
- 0 pp QoQ
Top 10 Chemicals & Petrochemicals companies on management guidance
See the sector's top 10 — free with your mobile number.
Sudarshan Pharma Industries Ltd Q1 FY27 key numbers
- Revenue
- Revenue from Operations for June 2026 quarter: ₹174.41 Cr.
As stated in Sudarshan Pharma Industries Ltd's Q1 FY27 investor presentation · published 25 Sept 2026. Reported figures, not investment advice.
Based on Sudarshan Pharma Industries Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Revenue from Operations for June 2026 quarter: ₹174.41 Cr (Page 39) - Revenue from Operations for June 2025 quarter: ₹145.26 Cr - Year-on-year (YoY) revenue growth for the quarter: ₹174.41 Cr vs ₹145.26 Cr (~20.1% increase) - Gross Profit Margin for June 2026 quarter: 14.13% (up from 11.05% in June 2025) - EBITDA Margin for June 2026 quarter: 9.81% (up from 8.43% in June 2025) - Explicit revenue outlook for FY 26-27: Target minimum export turnover of ₹100 Cr (Page 13) - Plans to strengthen API product range, increase focus on regulated and semi-regulated markets including Europe and USA - For June 2026 quarter (unaudited): - EBITDA: ₹17.11 Cr (up from ₹12.25 Cr in June 2025) → +39.7% YoY - EBITDA Margin: 9.81% (up from 8.43% in June 2025) - Profit after Tax (PAT): ₹5.61 Cr (up from ₹3.96 Cr in June 2025) → +41.7% YoY - PAT Margin: 3.21% (up from 2.72% in June 2025) - Yearly figures (FY26 vs FY25) show: - Operating EBITDA: ₹49.3 Cr (vs ₹39.9 Cr in FY25) → +23.6% - PAT: ₹23.3 Cr (FY26) vs ₹15.1 Cr (FY25) → +54.3% - PAT Margin improved accordingly.
From Sudarshan Pharma Industries Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Revenue from Operations for June 2026 quarter: ₹174.41 Cr (Page 39)
- Revenue from Operations for June 2025 quarter: ₹145.26 Cr
- Year-on-year (YoY) revenue growth for the quarter: ₹174.41 Cr vs ₹145.26 Cr (~20.1% increase)
- Gross Profit Margin for June 2026 quarter: 14.13% (up from 11.05% in June 2025)
- EBITDA Margin for June 2026 quarter: 9.81% (up from 8.43% in June 2025)
2 more points from Sudarshan Pharma Industries Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sudarshan Pharma Industries Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Nutraceuticals Plant project with a cost of Rs. 2.5 Cr and machinery cost of Rs. 1.15 Cr (2019-2020).
- Erection of oral liquid and capsule manufacturing unit at Palghar (2021-2022).
- Developing new products like Vitamin B1 and B6 under production-linked incentive (PLI) schemes (2021-2022).
- New unit development in Palghar (2023-2024).
2 more points from Sudarshan Pharma Industries Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sudarshan Pharma Industries Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Sudarshan Pharma Industries Ltd said on order book & pipeline — free account, 30 seconds.
Sudarshan Pharma Industries Ltd — Quarterly revenue & net profit
Sudarshan Pharma Industries Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 174 | 145 | +20.1% | 221 | -21% |
| Operating profit (EBITDA) | 16 | 11 | +44% | 20 | -21.3% |
| Operating margin | 9.12% | 7.6% | +1.5 pp | 9.14% | 0 pp |
| Profit before tax | 8 | 5 | +38.6% | 16 | -52.3% |
| Net profit (PAT) | 6 | 4 | +41.7% | 11 | -50.8% |
| EPS (₹) | 0.23 | 0.17 | +35.3% | 0.45 | -48.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹217 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sudarshan Pharma's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Alufluoride (Q1 FY27)
Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr
- POCL Enterprises (Q1 FY27)
466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto
- Devson Catalyst (Q1 FY27)
FY 2023-24: ₹5,577.59 Lakhs . Key investor presentation takeaways from Devson Catalyst Ltd's Q1 FY27 investor presentation — and how it ranks against sector pee
- Ambani Orgochem (Q1 FY27)
Financial highlights show Total Income in ₹ Lakhs: . Key investor presentation takeaways from Ambani Orgochem's Q1 FY27 investor presentation — and how it ranks
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sudarshan Pharma Industries Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sudarshan Pharma Industries Ltd Q1 FY27 results?
Revenue from Operations for June 2026 quarter: ₹174.41 Cr (Page 39) - Revenue from Operations for June 2025 quarter: ₹145.26 Cr - Year-on-year (YoY) revenue growth for the quarter: ₹174.41 Cr vs ₹145.26 Cr (~20.1% increase) - Gross Profit Margin for June 2026 quarter: 14.13% (up from 11.05% in June 2025) - EBITDA Margin for June 2026 quarter: 9.81% (up from 8.43% in June 2025) - Explicit revenue outlook for FY 26-27: Target minimum export turnover of ₹100 Cr (Page 13) - Plans to strengthen API product range, increase focus on regulated and semi-regulated markets including Europe and USA - For June 2026 quarter (unaudited): - EBITDA: ₹17.11 Cr (up from ₹12.25 Cr in June 2025) → +39.7% YoY - EBITDA Margin: 9.81% (up from 8.43% in June 2025) - Profit after Tax (PAT): ₹5.61 Cr (up from ₹3.96 Cr in June 2025) → +41.7% YoY - PAT Margin: 3.21% (up from 2.72% in June 2025) - Yearly figures (FY26 vs FY25) show: - Operating EBITDA: ₹49.3 Cr (vs ₹39.9 Cr in FY25) → +23.6% - PAT: ₹23.3 Cr (FY26) vs ₹15.1 Cr (FY25) → +54.3% - PAT Margin improved accordingly.
What is Sudarshan Pharma Industries Ltd share price analysis?
Sudarshan Pharma Industries Ltd currently shows a neutral. The stock trades at a P/E of 39.4 with a market cap of ₹990 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sudarshan Pharma Industries Ltd planning capital expenditure?
Nutraceuticals Plant project with a cost of Rs. 2.5 Cr and machinery cost of Rs. 1.15 Cr (2019-2020).
Keep Sudarshan Pharma Industries Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
